THE SHORT ANSWER
OptumRx Wegovy Coverage: Quick Answer
Coverage Depends on Your Plan Type
OptumRx covers Wegovy, but the covered indication varies by plan. As of January 2025, OptumRx added Wegovy to its Preferred Formulary for cardiovascular risk reduction—not weight loss. For UnitedHealthcare commercial plans using OptumRx, weight-loss coverage: Depends on your employer’s plan (prior authorization required when covered).[1]
If your pharmacy benefits are managed by OptumRx, here's what to expect:
- CV indication (heart disease) — Covered on OptumRx Preferred Formulary since Jan 1, 2025
- Weight loss indication — Coverage depends on your specific UHC or employer plan
- Prior authorization (PA) required — All Wegovy coverage requires pre-approval
- BMI criteria apply — Typically BMI (body mass index) ≥30, or ≥27 with a comorbidity (related health condition)
Important: OptumRx is a pharmacy benefit manager (PBM)—it's owned by UnitedHealth Group, which also owns UnitedHealthcare insurance. Your employer or insurer contracts with OptumRx to manage prescription benefits. Coverage details depend on your specific plan design—always verify directly.
Scale: OptumRx manages pharmacy benefits for over 100 million covered lives and processes about 23% of U.S. prescription claims—the third largest PBM after Express Scripts and CVS Caremark.[2]
For a complete overview of getting Wegovy covered regardless of insurer, see our full coverage guide or Is Wegovy Covered by Insurance?.
THE UNITEDHEALTHCARE CONNECTION
Understanding OptumRx as a PBM
OptumRx is a pharmacy benefit manager (PBM) owned by UnitedHealth Group—the same parent company that owns UnitedHealthcare insurance. This vertical integration means:
| Entity | Role | What It Does |
|---|---|---|
| UnitedHealth Group | Parent company | Owns both the insurer and PBM |
| UnitedHealthcare | Insurance company | Sets coverage policies, pays claims |
| OptumRx | Pharmacy benefit manager | Manages formulary, processes Rx claims |
Why Does This Matter?
Because OptumRx and UnitedHealthcare are under the same corporate umbrella, their formulary decisions are often aligned—but not always:
- OptumRx standard formulary — Covers Wegovy for CV risk reduction only (since Jan 2025)
- UHC commercial plans — Weight-loss coverage depends on your employer's plan; prior authorization required when covered
- Employer customization — Self-funded employers using OptumRx can customize coverage
- CHAMPVA — The VA program using OptumRx does NOT cover Wegovy for weight loss[3]
How to Check Your Specific Coverage
Your ID card tells you who to call. Look for "OptumRx" or "Optum" on your pharmacy card. Then call the number on your card AND your HR department to confirm:
- Is Wegovy covered for weight loss, CV risk reduction, or both?
- What are the prior authorization requirements?
- What tier is Wegovy on your plan?
2025-2026 COVERAGE
OptumRx Formulary & Tier Status
Here's the current status of GLP-1 medications on OptumRx formularies as of 2025-2026:
| Medication | Indication | Preferred Formulary | Notes |
|---|---|---|---|
| Wegovy (semaglutide) | CV risk reduction | Covered (Jan 2025) | PA required |
| Wegovy (semaglutide) | Weight loss | Plan-dependent | UHC commercial: Depends on your employer’s plan |
| Zepbound (tirzepatide) | Weight loss | Plan-dependent | Coverage varies |
| Ozempic (semaglutide) | Type 2 diabetes | Covered | Preferred |
| Mounjaro (tirzepatide) | Type 2 diabetes | Covered | PA may apply |
Understanding the CV vs Weight Loss Distinction
On March 8, 2024 (Wegovy injection), the FDA approved Wegovy injection for cardiovascular risk reduction in adults with obesity or overweight AND established cardiovascular disease (the tablets got the same indication with their approval, December 22, 2025 (Wegovy tablets)). This approval was based on the SELECT trial, which showed Wegovy reduced major cardiovascular events (heart attacks, strokes, CV death) by 20%.[4]
OptumRx's January 2025 formulary addition specifically covers this CV indication—meaning you must have both obesity/overweight AND established cardiovascular disease. If you're seeking Wegovy purely for weight loss, coverage depends on your specific plan.
Good News for Heart Disease Patients
If you have obesity plus established cardiovascular disease (previous heart attack, stroke, or peripheral artery disease), Wegovy coverage through OptumRx may be easier to obtain under the CV indication. Ask your doctor if this pathway applies to you.
Call Script: Checking Your Coverage
Call Script for OptumRx
"Hi, I'm calling to check coverage for a prescription medication. My member ID is [NUMBER]. I need to know:
- Is Wegovy (semaglutide) covered on my specific plan?
- Is it covered for weight management, cardiovascular risk reduction, or both?
- What tier is Wegovy on, and what's my estimated copay?
- What are the prior authorization requirements?
- Can I get this coverage determination in writing?"
OPTUMRX & UHC CRITERIA
Prior Authorization Requirements
All Wegovy coverage through OptumRx requires prior authorization. Requirements vary by indication:
For Weight Loss (UHC Commercial Plans)
Based on UHC prior authorization guidelines:[5]
- BMI ≥30, or ≥27 with a comorbidity (type 2 diabetes, hypertension, dyslipidemia/high cholesterol, or obstructive sleep apnea)
- Documentation of BMI measurements and weight-related health conditions
- Authorization period: 5 months for Wegovy (may require reauthorization)
- No contraindications — no personal or family history of medullary thyroid cancer or MEN2 (a rare genetic condition)
For CV Risk Reduction (OptumRx Preferred Formulary)
- Established cardiovascular disease — documented history of heart attack, stroke, or peripheral artery disease
- BMI ≥27 with cardiovascular disease
- FDA-labeled indication — reducing major adverse cardiovascular events (MACE)
Official Novo Nordisk Resources
Novo Nordisk provides free tools for OptumRx/UHC patients:[6]
For complete prior auth preparation, see our Wegovy prior authorization guide →
Your GLP-1 coverage,
denied approved
If OptumRx or UHC denies your Wegovy request, Honest Care can help you build a strong appeal with evidence-backed documentation.
Denied by OptumRx?
Get Help NowYOUR OPTIONS
What to Do If Denied
Appeals Can Work
65%+ of insurance appeals succeed—meaning roughly 2 out of every 3 people who appeal get approved.[7] Yet fewer than 1 in 100 denied claims are ever appealed[8]—those who do have a real chance of getting coverage.
Common OptumRx/UHC Denial Reasons for Wegovy
- "Does not meet criteria" — BMI or comorbidity requirements not documented
- "Weight loss not covered" — Your specific plan may only cover CV indication
- "Insufficient documentation" — Missing weight history or comorbidity records
- "Step therapy required" — Some plans require trying other medications first
What to Do:
Get the Denial in Writing
Request a written denial letter with the specific reason for denial.
Check If CV Indication Applies
If you have established cardiovascular disease (such as a prior heart attack or stroke) and obesity or overweight, your doctor may be able to prescribe under the CV indication, which has different coverage rules.
Request Peer-to-Peer Review
Your doctor can request a peer-to-peer review (a phone call between your doctor and OptumRx's medical director) to discuss medical necessity.
File Your Appeal
You have 180 days to appeal under ERISA. Need help? Use Honest Care to build your appeal →
Alternative Pathways
UnitedHealthcare Insurance?
If you have UnitedHealthcare insurance (not just OptumRx as PBM), check your specific plan benefits. See our UHC coverage guide →
NovoCare Savings Programs
If your plan excludes weight loss drugs entirely, NovoCare savings programs may help reduce out-of-pocket costs.
For complete appeal strategies, see our Wegovy appeals guide →
OPTUMRX WEGOVY COVERAGE
Frequently Asked Questions
Yes, but coverage depends on the indication. OptumRx added Wegovy to its Preferred Formulary in January 2025 for cardiovascular risk reduction (in adults with established cardiovascular disease and either obesity or overweight). For weight loss only, coverage depends on your specific UnitedHealthcare or employer plan—some UHC commercial plans cover Wegovy for weight loss with prior authorization, if the employer added that benefit.
OptumRx is the PBM; UnitedHealthcare is the insurer. Both are owned by UnitedHealth Group. OptumRx manages the formulary and processes pharmacy claims, while UnitedHealthcare sets the overall insurance coverage policies. You may have UHC insurance using OptumRx as the PBM, or you may have non-UHC insurance (like an employer plan) that uses OptumRx. Your specific coverage depends on your plan design, not just which company manages your pharmacy benefits.
Requirements vary by plan and indication. For weight loss on UHC commercial plans: BMI ≥30, or BMI ≥27 with a weight-related comorbidity (type 2 diabetes, hypertension, high cholesterol, or sleep apnea). Authorization is typically granted for 5 months and may require reauthorization. For CV risk reduction: you must have established cardiovascular disease (history of heart attack, stroke, or peripheral artery disease) plus obesity/overweight.
OptumRx's standard Preferred Formulary added Wegovy specifically for the FDA-approved CV indication (reducing heart attacks and strokes in adults with established cardiovascular disease and either obesity or overweight). The injection got this indication on March 8, 2024 (Wegovy injection) and the tablets on December 22, 2025 (Wegovy tablets), based on the SELECT trial. For weight loss coverage, you need to check your specific plan—many UHC commercial and employer plans cover weight loss with prior authorization, even if it's not on the standard OptumRx formulary.
First, request the denial reason in writing. Then file an internal appeal within 180 days (about 6 months) under ERISA rules. Include: documentation that you meet BMI criteria, evidence of weight-related health conditions, and a Letter of Medical Necessity from your doctor. Your doctor can also request a peer-to-peer review with OptumRx's medical director. Research shows 65%+ of insurance appeals succeed—roughly 2 out of every 3 people who appeal get approved.
Not for weight loss. CHAMPVA (the VA program for dependents) uses OptumRx but specifically excludes coverage for weight loss medications including Wegovy, Saxenda, and Zepbound. CHAMPVA may cover Wegovy for other indications like MASH (metabolic-associated steatohepatitis) or cardiovascular risk reduction, but not for obesity treatment alone. Check with CHAMPVA directly for your specific situation.
WHAT'S COMING
OptumRx Coverage Outlook for 2026
OptumRx Wegovy coverage is expected to remain stable through 2026. Key developments to watch:
- Medicare — The Medicare GLP-1 Bridge is live (July 1, 2026 – December 31, 2027): Wegovy for weight loss for $50 per monthly fill, with conditions, outside your OptumRx Part D plan
- Oral Wegovy — FDA approved oral semaglutide for obesity in December 2025; OptumRx formulary status TBD
- Employer trends — More employers are adding GLP-1 coverage due to workforce demand
For Medicare-specific updates, see our Medicare guide.
YOUR PATH FORWARD
What's Next
Wegovy Coverage: Other Major Insurers & PBMs
Coverage depends on your insurance plan and PBM. See other guides:
- CVS Caremark — Wegovy is preferred GLP-1 since July 2025
- Express Scripts — Coverage varies by plan
- UnitedHealthcare — Works with OptumRx; coverage varies
- Blue Cross Blue Shield — Varies by state/plan
- Cigna — Uses Express Scripts as PBM
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedReferences
- PSG Consults. (2024). "2025 Formulary Changes: Optum Rx." psgconsults.com
- Becker's Hospital Review. (2024). "Top PBMs by 2024 market share." beckershospitalreview.com
- OptumRx. (2025). "Welcome to OptumRx - CHAMPVA." welcome.optumrx.com
- Lincoff AM, et al. (2023). "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine. nejm.org
- UnitedHealthcare. (2025). "Plans with Weight Loss/Appetite Suppression Medication Coverage." uhcprovider.com
- Novo Nordisk. (2025). "Wegovy Coverage and Savings." wegovy.com
- American Medical Association. (2024). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" ama-assn.org
- KFF. (2023). "Claims Denials and Appeals in ACA Marketplace Plans in 2023." kff.org
Last updated October 6, 2026 · Key facts verified October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.